批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2020/06/24 |
SUPPL-41(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2016/02/09 |
SUPPL-39(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2015/02/06 |
SUPPL-36(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2013/04/26 |
SUPPL-38(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2013/02/21 |
SUPPL-37(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2012/04/27 |
SUPPL-35(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
2012/04/13 |
SUPPL-32(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
2011/06/24 |
SUPPL-33(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
2009/10/22 |
SUPPL-31(补充) |
Approval |
Efficacy |
PRIORITY
|
|
|
2006/08/17 |
SUPPL-26(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2005/05/18 |
SUPPL-22(补充) |
Approval |
Efficacy |
PRIORITY
|
|
|
2005/02/22 |
SUPPL-24(补充) |
Approval |
Efficacy |
PRIORITY
|
|
|
2004/12/16 |
SUPPL-23(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2003/04/23 |
SUPPL-19(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2003/01/22 |
SUPPL-17(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2002/09/13 |
SUPPL-15(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2001/11/28 |
SUPPL-16(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2001/10/04 |
SUPPL-14(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2001/06/07 |
SUPPL-10(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2001/05/24 |
SUPPL-12(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2001/04/02 |
SUPPL-11(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2001/03/29 |
SUPPL-13(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2000/12/27 |
SUPPL-9(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2000/06/14 |
SUPPL-8(补充) |
Approval |
Labeling |
STANDARD
|
|
|
1999/12/08 |
SUPPL-6(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
1999/08/11 |
SUPPL-5(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
1999/07/28 |
SUPPL-4(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
1998/12/07 |
SUPPL-1(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
1998/11/16 |
SUPPL-2(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
1998/06/04 |
ORIG-1(原始申请) |
Approval |
Type 1 - New Molecular Entity |
STANDARD
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
活性成分:CANDESARTAN CILEXETIL 剂型/给药途径:TABLET;ORAL 规格:4MG 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
020838 |
001 |
NDA |
ATACAND |
CANDESARTAN CILEXETIL |
TABLET;ORAL |
4MG |
Prescription |
Yes |
No |
AB |
1998/06/04
|
ANI PHARMS |
078702 |
001 |
ANDA |
CANDESARTAN CILEXETIL |
CANDESARTAN CILEXETIL |
TABLET;ORAL |
4MG |
Prescription |
No |
No |
AB |
2013/05/03
|
MYLAN |
203813 |
001 |
ANDA |
CANDESARTAN CILEXETIL |
CANDESARTAN CILEXETIL |
TABLET;ORAL |
4MG |
Prescription |
No |
No |
AB |
2016/12/05
|
MACLEODS PHARMS LTD |
091390 |
001 |
ANDA |
CANDESARTAN CILEXETIL |
CANDESARTAN CILEXETIL |
TABLET;ORAL |
4MG |
Prescription |
No |
No |
AB |
2017/08/23
|
ZYDUS LIFESCIENCES |
210302 |
001 |
ANDA |
CANDESARTAN CILEXETIL |
CANDESARTAN CILEXETIL |
TABLET;ORAL |
4MG |
Prescription |
No |
No |
AB |
2018/12/04
|
ALEMBIC |
活性成分:CANDESARTAN CILEXETIL 剂型/给药途径:TABLET;ORAL 规格:8MG 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
020838 |
002 |
NDA |
ATACAND |
CANDESARTAN CILEXETIL |
TABLET;ORAL |
8MG |
Prescription |
Yes |
No |
AB |
1998/06/04
|
ANI PHARMS |
078702 |
002 |
ANDA |
CANDESARTAN CILEXETIL |
CANDESARTAN CILEXETIL |
TABLET;ORAL |
8MG |
Prescription |
No |
No |
AB |
2013/05/03
|
MYLAN |
203813 |
002 |
ANDA |
CANDESARTAN CILEXETIL |
CANDESARTAN CILEXETIL |
TABLET;ORAL |
8MG |
Prescription |
No |
No |
AB |
2016/12/05
|
MACLEODS PHARMS LTD |
091390 |
002 |
ANDA |
CANDESARTAN CILEXETIL |
CANDESARTAN CILEXETIL |
TABLET;ORAL |
8MG |
Prescription |
No |
No |
AB |
2017/08/23
|
ZYDUS LIFESCIENCES |
210302 |
002 |
ANDA |
CANDESARTAN CILEXETIL |
CANDESARTAN CILEXETIL |
TABLET;ORAL |
8MG |
Prescription |
No |
No |
AB |
2018/12/04
|
ALEMBIC |
206233 |
001 |
ANDA |
CANDESARTAN CILEXETIL |
CANDESARTAN CILEXETIL |
TABLET;ORAL |
8MG |
Prescription |
No |
No |
AB |
2023/08/21
|
PRINSTON INC |
活性成分:CANDESARTAN CILEXETIL 剂型/给药途径:TABLET;ORAL 规格:16MG 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
020838 |
003 |
NDA |
ATACAND |
CANDESARTAN CILEXETIL |
TABLET;ORAL |
16MG |
Prescription |
Yes |
No |
AB |
1998/06/04
|
ANI PHARMS |
078702 |
003 |
ANDA |
CANDESARTAN CILEXETIL |
CANDESARTAN CILEXETIL |
TABLET;ORAL |
16MG |
Prescription |
No |
No |
AB |
2013/05/03
|
MYLAN |
203813 |
003 |
ANDA |
CANDESARTAN CILEXETIL |
CANDESARTAN CILEXETIL |
TABLET;ORAL |
16MG |
Prescription |
No |
No |
AB |
2016/12/05
|
MACLEODS PHARMS LTD |
091390 |
003 |
ANDA |
CANDESARTAN CILEXETIL |
CANDESARTAN CILEXETIL |
TABLET;ORAL |
16MG |
Prescription |
No |
No |
AB |
2017/08/23
|
ZYDUS LIFESCIENCES |
210302 |
003 |
ANDA |
CANDESARTAN CILEXETIL |
CANDESARTAN CILEXETIL |
TABLET;ORAL |
16MG |
Prescription |
No |
No |
AB |
2018/12/04
|
ALEMBIC |
206233 |
002 |
ANDA |
CANDESARTAN CILEXETIL |
CANDESARTAN CILEXETIL |
TABLET;ORAL |
16MG |
Prescription |
No |
No |
AB |
2023/08/21
|
PRINSTON INC |
活性成分:CANDESARTAN CILEXETIL 剂型/给药途径:TABLET;ORAL 规格:32MG 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
020838 |
004 |
NDA |
ATACAND |
CANDESARTAN CILEXETIL |
TABLET;ORAL |
32MG |
Prescription |
Yes |
Yes |
AB |
1998/06/04
|
ANI PHARMS |
078702 |
004 |
ANDA |
CANDESARTAN CILEXETIL |
CANDESARTAN CILEXETIL |
TABLET;ORAL |
32MG |
Prescription |
No |
No |
AB |
2013/05/03
|
MYLAN |
203813 |
004 |
ANDA |
CANDESARTAN CILEXETIL |
CANDESARTAN CILEXETIL |
TABLET;ORAL |
32MG |
Prescription |
No |
No |
AB |
2016/12/05
|
MACLEODS PHARMS LTD |
209119 |
001 |
ANDA |
CANDESARTAN CILEXETIL |
CANDESARTAN CILEXETIL |
TABLET;ORAL |
32MG |
Prescription |
No |
No |
AB |
2017/06/20
|
ALEMBIC |
091390 |
004 |
ANDA |
CANDESARTAN CILEXETIL |
CANDESARTAN CILEXETIL |
TABLET;ORAL |
32MG |
Prescription |
No |
No |
AB |
2017/08/23
|
ZYDUS LIFESCIENCES |
206233 |
003 |
ANDA |
CANDESARTAN CILEXETIL |
CANDESARTAN CILEXETIL |
TABLET;ORAL |
32MG |
Prescription |
No |
No |
AB |
2023/08/21
|
PRINSTON INC |